Eli Lilly and Company $LLY Shares Acquired by SVB Wealth LLC

SVB Wealth LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 13.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,775 shares of the company’s stock after purchasing an additional 1,245 shares during the quarter. SVB Wealth LLC’s holdings in Eli Lilly and Company were worth $9,910,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $30,000. Miller Global Investments LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $1,110.37 on Wednesday. The firm has a market cap of $1.05 trillion, a P/E ratio of 39.44, a price-to-earnings-growth ratio of 1.20 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The stock has a 50-day simple moving average of $1,022.46 and a 200-day simple moving average of $1,018.08.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price target for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,230.89.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its neuroscience pipeline with a new research collaboration with BioArctic, combining Lilly’s drug candidate with BioArctic’s BrainTransporter technology to develop a potential treatment for neurodegenerative disease; the deal included a $30 million upfront payment and reinforces Lilly’s pipeline growth strategy. BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology
• Positive Sentiment: The company was also cleared to advance its planned acquisition of Centessa by the High Court of Justice of England and Wales, supporting Lilly’s efforts to broaden its drug portfolio and add to future growth drivers. Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
• Positive Sentiment: Reuters reported that Lilly expects to launch its weight-loss pill in Europe and Britain in late 2026 or early 2027, extending the commercial opportunity for its obesity franchise outside the U.S. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
• Positive Sentiment: Analysts and commentary continued to highlight Lilly’s strong growth profile, including surging sales for Mounjaro and Zepbound and optimism around the still-expanding GLP-1 market, which supports the stock’s premium valuation. Eli Lilly (LLY) Opens Data Center to Smaller Biotech Firms as It Chases Drug Discoveries
• Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, a routine capital return update that is supportive but not likely to move the stock materially on its own. Lilly declares third-quarter 2026 dividend
• Neutral Sentiment: The healthcare sector itself was firmer in afternoon trading, providing a favorable backdrop for Eli Lilly alongside broader rotation into defensive/healthcare names. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Neutral Sentiment: Some headlines noted investor enthusiasm around Lilly’s stock and its GLP-1 leadership, but these were largely commentary pieces rather than new fundamental catalysts. Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
• Negative Sentiment: One Reuters report said Trump pricing policy could complicate Lilly’s obesity-drug launches in Europe, creating some regulatory and pricing uncertainty for an important growth franchise. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.